PMID- 25750540
OWN - NLM
STAT- MEDLINE
DCOM- 20151019
LR  - 20221207
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Print)
IS  - 1176-6344 (Linking)
VI  - 11
DP  - 2015
TI  - Extended-release niacin/laropiprant significantly improves lipid levels in type 2 
      diabetes mellitus irrespective of baseline glycemic control.
PG  - 165-72
LID - 10.2147/VHRM.S70907 [doi]
AB  - BACKGROUND: The degree of glycemic control in patients with type 2 diabetes 
      mellitus (T2DM) may alter lipid levels and may alter the efficacy of 
      lipid-modifying agents. OBJECTIVE: Evaluate the lipid-modifying efficacy of 
      extended-release niacin/laropiprant (ERN/LRPT) in subgroups of patients with T2DM 
      with better or poorer glycemic control. METHODS: Post hoc analysis of clinical 
      trial data from patients with T2DM who were randomized 4:3 to double-blind 
      ERN/LRPT or placebo (n=796), examining the lipid-modifying effects of ERN/LRPT in 
      patients with glycosylated hemoglobin or fasting plasma glucose levels above and 
      below median baseline levels. RESULTS: At Week 12 of treatment, ERN/LRPT 
      significantly improved low-density lipoprotein cholesterol, high-density 
      lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol, 
      triglycerides, and lipoprotein (a), compared with placebo, with equal efficacy in 
      patients above or below median baseline glycemic control. Compared with placebo, 
      over 36 weeks of treatment more patients treated with ERN/LRPT had worsening of 
      their diabetes and required intensification of antihyperglycemic medication, 
      irrespective of baseline glycemic control. Incidences of other adverse 
      experiences were generally low in all treatment groups. CONCLUSION: The 
      lipid-modifying effects of ERN/LRPT are independent of the degree of baseline 
      glycemic control in patients with T2DM (NCT00485758).
FAU - Bays, Harold E
AU  - Bays HE
AD  - Louisville Metabolic & Atherosclerosis Research Center (L-MARC), Louisville, KY, 
      USA.
FAU - Brinton, Eliot A
AU  - Brinton EA
AD  - Utah Foundation for Biomedical Research, Salt Lake City, UT, USA.
FAU - Triscari, Joseph
AU  - Triscari J
AD  - Merck & Co, Inc., Whitehouse Station, NJ, USA.
FAU - Chen, Erluo
AU  - Chen E
AD  - Merck & Co, Inc., Whitehouse Station, NJ, USA.
FAU - Maccubbin, Darbie
AU  - Maccubbin D
AD  - Merck & Co, Inc., Whitehouse Station, NJ, USA.
FAU - MacLean, Alexandra A
AU  - MacLean AA
AD  - Merck & Co, Inc., Whitehouse Station, NJ, USA.
FAU - Gibson, Kendra L
AU  - Gibson KL
AD  - Merck & Co, Inc., Whitehouse Station, NJ, USA.
FAU - Ruck, Rae Ann
AU  - Ruck RA
AD  - Merck & Co, Inc., Whitehouse Station, NJ, USA.
FAU - Johnson-Levonas, Amy O
AU  - Johnson-Levonas AO
AD  - Merck & Co, Inc., Whitehouse Station, NJ, USA.
FAU - O'Neill, Edward A
AU  - O'Neill EA
AD  - Merck & Co, Inc., Whitehouse Station, NJ, USA.
FAU - Mitchel, Yale B
AU  - Mitchel YB
AD  - Merck & Co, Inc., Whitehouse Station, NJ, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT00485758
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150224
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Combinations)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Indoles)
RN  - 0 (Lipids)
RN  - 0 (MK-0524)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 2679MF687A (Niacin)
SB  - IM
MH  - Aged
MH  - Biomarkers/*blood
MH  - Blood Glucose/*drug effects/metabolism
MH  - Delayed-Action Preparations
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Drug Interactions
MH  - Dyslipidemias/blood/diagnosis/*drug therapy
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Hypolipidemic Agents/adverse effects/*therapeutic use
MH  - Indoles/adverse effects/*therapeutic use
MH  - Lipids/*blood
MH  - Male
MH  - Middle Aged
MH  - Niacin/adverse effects/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC4348131
OTO - NOTNLM
OT  - HDL
OT  - LDL
OT  - hyperglycemia
OT  - lipid-modifying agents
OT  - triglycerides
EDAT- 2015/03/10 06:00
MHDA- 2015/10/20 06:00
PMCR- 2015/02/24
CRDT- 2015/03/10 06:00
PHST- 2015/03/10 06:00 [entrez]
PHST- 2015/03/10 06:00 [pubmed]
PHST- 2015/10/20 06:00 [medline]
PHST- 2015/02/24 00:00 [pmc-release]
AID - vhrm-11-165 [pii]
AID - 10.2147/VHRM.S70907 [doi]
PST - epublish
SO  - Vasc Health Risk Manag. 2015 Feb 24;11:165-72. doi: 10.2147/VHRM.S70907. 
      eCollection 2015.